07:00 , Aug 3, 2015 |  BioCentury  |  Finance

Taiwan's post-bubble prognosis

More than a year after BioCentury chronicled investor enthusiasm for biotechs in Taiwan, the bubble has deflated. It's tempting to blame the downturn simply on retail investors who didn't get up to speed as quickly...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Burixafor: Phase I/II started

TaiGen began an open-label, dose-finding, Chinese Phase I/II trial to evaluate burixafor in combination with fludarabine and cytarabine chemotherapy in up to 15 patients. TaiGen Biopharmaceuticals Holdings Ltd. (GreTai:4157), Taipei, Taiwan   Product: Burixafor ( TG-0054)...
01:09 , May 5, 2015 |  BC Extra  |  Clinical News

TaiGen starts burixafor trial in China

TaiGen Biopharmaceuticals Holdings Ltd. (GreTai:4157) began a Phase I/II trial in China of burixafor ( TG-0054), a CXC chemokine receptor 4 ( CXCR4) inhibitor, to treat relapsed or refractory acute myelogenous leukemia (AML). The open-label,...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver fibrosis CXC chemokine receptor 4 (CXCR4; NPY3R); CXCR7 Mouse studies suggest agonizing CXCR7 or inhibiting...
07:00 , Jun 17, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) CXC chemokine receptor 4 (CXCR4; NPY3R) Mouse studies suggest that CXCR4 antagonists could...
08:00 , Mar 4, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Hypoxia-inducible factor 1 (HIF1); chemokine CXC motif ligand 12 (CXCL12; SDF-1); CXC chemokine receptor 4 (CXCR4;...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

TG-0054: Phase II start

This month, TaiGen will begin an open-label, single ascending-dose Phase II trial to evaluate 2.24 and 3.14 mg/kg of intravenous TG-0045. TaiGen Biotechnology Co. Ltd., Taipei, Taiwan   Product: TG-0054   Business: Cancer   Molecular target: ...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

TG-0054: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 64 healthy volunteers showed that TG-0054 was well tolerated and rapidly mobilized stem and endothelial progenitor cells from bone marrow to peripheral blood. The mobilized cells peaked...
08:00 , Jan 26, 2009 |  BioCentury  |  Finance

Ebb & Flow

Taiwan's Taigen Biotechnology was able to raise $37 million in a series C round last week, but at a steep discount that helps explain why it's sometimes better to be an early stage investor. The...
07:00 , Sep 4, 2008 |  BC Innovations  |  Targets & Mechanisms

CXCR4 for CNS Infections

The purpose of the blood-brain barrier is to limit trafficking of leukocytes into the immune-privileged CNS. However, this becomes an undesirable trait when trying to clear acute CNS infections.1 Indeed, one component of the body's...